Fibroblast activation protein: Differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors

Journal of Investigative Dermatology

Volumn 120, Issue 2, 2003, Pages 182-188

  Huber, Margit A ^a   Kraut, Norbert ^b   Park, John E ^c   Schubert, Roland D ^a   Rettig, Wolfgang J ^b   Peter, Ralf U ^a,d   Garin Chesa, Pilar ^c,e  

^a UNIVERSITY OF ULM   (Germany)

^b BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d BUNDESWEHRKRANKENHAUS ULM   (Germany)

^e UNIVERSITY OF VIENNA   (Austria)

Author keywords

Melanoma; Metastasis; Tumor progression; Tumor stroma

Indexed keywords

FIBROBLAST ACTIVATION PROTEIN; SERINE PROTEINASE; UNCLASSIFIED DRUG; FAP PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; CARCINOGENESIS; CELL ACTIVATION; CELL PROLIFERATION; CELL SUBPOPULATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MELANOCYTIC NEVUS; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN METASTASIS; TUMOR CELL; TUMOR GROWTH; BIOSYNTHESIS; ENZYMOLOGY; METABOLISM; METASTASIS; NEOPLASM; PATHOLOGY; PIGMENTED NEVUS; SKIN TUMOR; STROMA CELL;

ANTIGENS, NEOPLASM; FIBROBLASTS; HUMANS; MELANOMA; NEOPLASMS; NEVUS, PIGMENTED; SERINE ENDOPEPTIDASES; SKIN NEOPLASMS; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037318082     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2003.12035.x     Document Type: Article

References (35)

1. Albino AP, Sozzi G, Nanus DM, Jhanwar SC, Houghton AN: Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. Oncogene 7:2315-2321, 1992
2. Banerjee SS, Harris M: Morphological and immunophenotypic variations in malignant melanoma. Histopathology 36:387-402, 2000
3. Bittner M, Meltzer P, Chen Y, et al: Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406:536-540, 2000
4. Byers HR, Bhawan J: Pathologic parameters in the diagnosis and prognosis of primary cutaneous melanoma. Hematol Oncol Clin North Am 12:717-735, 1998
5. Chin L, Merlino G, DePinho RA: Malignant melanoma: modern black plague and genetic black box. Genes Dev 12:3467-3481, 1998
6. Christian S, Ahorn H, Novatchkova M, et al: Molecular cloning and characterization of EndoGlyx-1, an EMILIN-like multisubunit glycoprotein of vascular endothelium. J Biol Chem 276:48588-48595, 2001
7. Clarijs R, Otte-Holler I, Ruiter DJ, de Waal RM: Presence of a fluid-conducting meshwork in xenografted cutaneous and primary human uveal melanoma. Invest Ophthalmol Vis Sci 43:912-918, 2002
8. Clark EA, Golub TR, Lander ES, Hynes RO: Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532-535, 2000
9. Clark WH Jr, Elder DE, Guerry D: 4th, Epstein MN, Greene MH, Van Horn M: A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 15:1147-1165, 1984
10. Elder DE, Rodeck U, Thurin J, Cardillo F, Clark WH, Stewart R, Herlyn M: Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas. Cancer Res 49:5091-5096, 1989
11. Fidler IJ: Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 87:1588-1592, 1995
12. Folberg R, Peér J, Gruman LM, et al: The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study. Hum Pathol 23:1298-1305, 1992
13. Foss AJ, Alexander RA, Hungerford JL, Harris AL, Cree IA, Lightman S: Reassessment of the PAS patterns in uveal melanoma. Br J Ophthalmol 81:240-246, 1997
14. Garin-Chesa P, Rettig WJ, Melamed MR, Old LJ, Niman HL: Expression of p21ras in normal and malignant human tissues: lack of association with proliferation and malignancy. Proc Natl Acad Sci USA 84:3234-3238, 1987
15. Garin-Chesa P, Rettig WJ, Thomson TM, Old LJ, Melamed MR: Immunohistochemical analysis of nerve growth factor receptor expression in normal and malignant human tissues. J Histochem Cytochem 36:383-389, 1988
16. Garin-Chesa P, Old LJ, Rettig WJ: Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA 87:7235-7239, 1990
17. Halachmi S, Gilchrest BA: Update on genetic events in the pathogenesis of melanoma. Curr Opin Oncol 13:129-136, 2001
18. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364, 1996
19. Hofmann UB, Westphal JR, Van Muijen GN, Ruiter DJ: Matrix metalloproteinases in human melanoma. J Invest Dermatol 115:337-344, 2000
20. Houghton AN, Albino AP, Cordon-Cardo C, Davis LJ, Eisinger M: Cell surface antigens of human melanocytes and melanoma. Expression of adenosine deaminase binding protein is extinguished with melanocyte transformation. J Exp Med 167:197-212, 1988
21. Iyer VR, Eisen MB, Ross DT, et al: The transcriptional program in the response of human fibroblasts to serum. Science 283:83-87, 1999
22. Liotta LA, Kohn EC: The microenvironment of the turnout-host interface. Nature 411:375-379, 2001
23. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327-336, 1991
24. Maniotis AJ, Folberg R, Hess A, et al: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155:739-752, 1999
25. McDonald DM, Munn L, Jain RK: Vasculogenic mimicry: how convincing, how novel, and how significant? Am J Pathol 156:383-388, 2000
26. McMasters KM, Sondak VK, Lotze MT, Ross MI: Recent advances in melanoma staging and therapy. Ann Surg Oncol 1999:467-475, 1999
27. Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ: Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 274:36505-36512, 1999
28. Rettig WJ, Garin-Chesa P, Beresford HR, Oettgen HF, Melamed MR, Old LJ: Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc Natl Acad Sci USA 85:3110-3114, 1988
29. Rettig WJ, Garin-Chesa P, Healey JH, et al: Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res 53:3327-3335, 1993
30. Rettig WJ, Su SL, Fortunato SR, et al: Fibroblast activation protein: purification, epitope mapping and induction by growth factors. Int J Cancer 58:385-392, 1994
31. Ruiter D, Bogenrieder T, Elder D, Herlyn M: Melanoma-stroma interactions: structural and functional aspects. Lancet Oncol 3:35-43, 2002
32. Sanz-Moncasi MP, Garin-Chesa P, Stockert E, Jaffe EA, Old LJ, Rettig WJ: Identification of a high molecular weight endothelial cell surface glycoprotein, endoGlyx-1, in normal and tumor blood vessels. Lab Invest 71:366-373, 1994
33. Scanlan MJ, Raj BK, Calvo B, et al: Molecular cloning of fibroblast activation protein α, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci USA 91:5657-5661, 1994
34. Warso MA, Maniotis AJ, Chen X, et al: Prognostic significance of periodic acid- - Schiff-positive patterns in primary cutaneous melanoma. Clin Cancer Res 7:473-477, 2001
35. Wesley UV, Albino AP, Tiwari S, Houghton AN: A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med 190:311-322, 1999